Yahoo Finance • 3 months ago

Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?

We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Immunovant, Inc. (NASDAQ:IMVT) ranks among the worst performing stocks to buy on the dip. Capital markets demonstrated inc... Full story

Yahoo Finance • 11 months ago

Should You Invest in Immunovant (IMVT)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% (Institutional Shares) in the quarter compared to... Full story

Yahoo Finance • last year

11 Stocks Insiders and Billionaires Are Crazy About

In this article, we will take a detailed look at the11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled O... Full story

Yahoo Finance • last year

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402 IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1... Full story

Yahoo Finance • last year

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402 IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1... Full story

Yahoo Finance • last year

Immunovant to Present at Upcoming Investor Conferences

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc.(Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief execu... Full story

Yahoo Finance • last year

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Positive initial Phase 1 data for IMVT-1402 announced, bolstering best-in-class potential Initial 600 mg multiple-ascending dose (MAD) cohort data for IMVT-1402 expected in November 2023 Initial Phase 2 proof-of-concept data for batoclimab... Full story

Yahoo Finance • last year

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the closing of its previously announ... Full story

Yahoo Finance • last year

Immunovant Announces Pricing of $450 Million Common Stock Financing

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten publ... Full story

Yahoo Finance • last year

Immunovant Announces Proposed Offering of $300 Million of Common Stock

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the commencement of a proposed unde... Full story

Yahoo Finance • last year

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (... Full story

Yahoo Finance • last year

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (... Full story

Yahoo Finance • last year

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report initial IMVT-14... Full story

Yahoo Finance • 2 years ago

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023 A Phase 3 clinical trial of batoclimab in thyroid eye disease (TED) and a Phase 2b clinical trial in chronic inflammatory demyelinating polyneuro... Full story

Yahoo Finance • 2 years ago

12 Best Small-Cap Healthcare Stocks To Buy Now

In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now. Macroeconomic headwinds and recessionary concerns will... Full story

Yahoo Finance • 2 years ago

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc.(Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chie... Full story

Yahoo Finance • 2 years ago

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

IMVT-1402, a next generation, subcutaneously administered, neonatal fragment crystallizable receptor (FcRn) inhibitor unveiled New development programs for batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’... Full story

Yahoo Finance • 2 years ago

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Ch... Full story

Yahoo Finance • 2 years ago

UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab

Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first half of 2024 Plan to initiate a Phase 2 t... Full story

Yahoo Finance • 2 years ago

Immunovant Announces Two New Development Programs for Batoclimab

Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first half of 2024 Plan to initiate a Phase 2 t... Full story